Founded July 2019
Stage Technology development
Investors Trendlines Incubators Israel, Bayer Trendlines Ag Innovation Fund
CEO Orly Savion, PhD
EcoPhage is an agri-biotechnology company, developing sustainable and effective, phage-based crop protection solutions to manage bacterial plant diseases. Phages are naturally occurring viruses (bacteriophages) that target bacteria and are safe and inert to humans, animals and plants.
The company’s proprietary technology platform is licensed from the Weizmann Institute of Science, developed by Professor Rotem Sorek, a recognized world leader known for his groundbreaking research on the interactions between bacteria and bacteriophages and a scientific founder of several companies.
Our platform technology consists of screening and characterization methodology of phage collections, resulting in the selection of the most promising phage candidates (“super phages”). These phages form a basis for highly effective and sustainable phage cocktails that meet multiple agricultural product attributes for antimicrobial crop protection.
The company is backed by The Trendlines Group, the Bayer Trendlines Ag Innovation Fund and the Israel Innovation Authority (IIA).
• Received two investments from the Bayer Trendlines Ag Innovation Fund
• Multiple distinct, active phages identified and presenting high efficacy against target bacteria
• Several leading cocktails present promising results in vitro and in plant assays
In the Media
September 2020: Greener Farming – EcoPhage
July 2020: 8 Israeli inventions for greener farming
February 2020: Viruses join the battle against crop disease
January 2020: Farmers and Bacteriophages Against Bacteria (Hebrew)
Orly has accumulated wide scientific-technological experience in diverse disciplines and holds strong business development capabilities. Prior to joining EcoPhage, Orly led the formation of a broad portfolio of technological licensing deals at Yeda R&D, the technology transfer arm of the Weizmann Institute of Science (WIS), where she served as a senior director of business development. As part of her role at Yeda, Orly initiated substantial multi-million commercialization achievements including startup spinouts, licensing deals and strategic collaborations, and business activities with MNCs, SMEs, VCs and accelerators, combining relations with the IIA and the academic staff.
Orly completed her PhD at the WIS biology & chemistry departments, and holds a MSc and BSc in engineering of biotechnology and food from the Technion, Israel Institute of Technology
Experienced biotechnology entrepreneur with a strong academic background; played a key role in the commercialization of technologies from academia through licensing and founding a start-up.
Led R&D teams that successfully generated significant results for the respective companies: generating value, raising funds, and forming strategic international collaborations; actively participated in the presentations and discussions that led to collaborations, joint ventures and licensing agreements, including the acquisition of Rosetta Green by Monsanto; PhD, molecular biology, Tel Aviv University
Recognized world expert in phage biology and phage-bacteria interactions. Full Professor, Department of Molecular Genetics, The Weizmann Institute of Science.
Farmers are seeking for effective and sustainable solutions to combat 200+ bacterial diseases, causing billions of dollars in annual yield damage in major crops globally.
Current widely used synthetic pesticides include copper and antibiotics; yet, these are insufficient due to poor efficacy, resistance development of the disease-causing bacteria, environmental impacts and use limitation due to regulation and public pressure.
Sustainable antibacterial biopesticides will attain healthy disease-free plants, provide safe food for a growing global population, and minimize the impact of agricultural practices on the environment.
The global biopesticide market size was USD 4.40 billion in 2019 and is expected to reach USD 10.63 billion by 2027, exhibiting a CARG of 13.1% during the forecast period (source).